Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy.

Stafford WC, Peng X, Olofsson MH, Zhang X, Luci DK, Lu L, Cheng Q, Trésaugues L, Dexheimer TS, Coussens NP, Augsten M, Ahlzén HM, Orwar O, Östman A, Stone-Elander S, Maloney DJ, Jadhav A, Simeonov A, Linder S, Arnér ESJ.

Sci Transl Med. 2018 Feb 14;10(428). pii: eaaf7444. doi: 10.1126/scitranslmed.aaf7444.

PMID:
29444979
2.

Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads.

Kaminska KK, Bertrand HC, Tajima H, Stafford WC, Cheng Q, Chen W, Wells G, Arner ES, Chew EH.

Oncotarget. 2016 Jun 28;7(26):40233-40251. doi: 10.18632/oncotarget.9579.

3.

Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells.

Sachweh MC, Stafford WC, Drummond CJ, McCarthy AR, Higgins M, Campbell J, Brodin B, Arnér ES, Laín S.

Oncotarget. 2015 Jun 30;6(18):16488-506.

4.

Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay.

Prast-Nielsen S, Dexheimer TS, Schultz L, Stafford WC, Cheng Q, Xu J, Jadhav A, Arnér ES, Simeonov A.

Free Radic Biol Med. 2011 May 1;50(9):1114-23. doi: 10.1016/j.freeradbiomed.2011.01.020. Epub 2011 Jan 22.

Supplemental Content

Loading ...
Support Center